Amgen (AMGN) closed at $328.35 on Friday, 2.29% higher on the day. Amgen's stock price has increased 14.00% so far this year, ...

Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Amgen (AMGN – Research Report) today and set a price target of $319.00.

The Dow Jones Industrial Average and the other major stock indexes traded lower Friday as investors reacted to more inflation ...

Caleb Carr’s company started in a garage when he was a student at the University of Colorado Denver. He was 18 years old but ...

Somerset Trust Co trimmed its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 0.6% in the third quarter, according to its ...

The offering will fund testing of a potential rival to Amgen’s Tezspire and is already the sixth for an immune drug developer this year, the most since 2021.

Cwm LLC boosted its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 0.7% during the 3rd quarter, according to the ...

Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff ...

The growing occurrence of pediatric conditions like HIV, cancer, diabetes, and others is boosting the need for treatments specifically designed for children, making pediatric drug development ...

The investment community will be closely monitoring the performance of Amgen in its forthcoming earnings report. The company is scheduled to release its earnings on October 30, 2024. It is anticipated ...

On CNBC's "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners named Deere & Company as his final trade.